- Array Advances a Novel Class of KSP Inhibitors as Promising Anti-Cancer
BOULDER, Colo., March 14 /PRNewswire-FirstCall/ -- Array BioPharma Inc.
(Nasdaq: ARRY) today announced that a scientific poster on its KSP anti-cancer
program will be presented at the 4th International Symposium on Targeted
Anti-Cancer Therapies in Amsterdam, The Netherlands.
Event: 4th International Symposium on Targeted Anti-cancer Therapies
Poster: "ARRY-649: A Potent and Efficacious KSP Inhibitor" Abstract
and Poster # P.203
Date: March 16 - 18, 2006
Location: Vrije University, Amsterdam, The Netherlands
If you are interested in viewing Array's KSP poster, as well as other
Array posters, please visit www.arraybiopharma.com .
Array has invented Kinesin Spindle Protein (KSP) inhibitors with
sub-nanomolar potency in both enzymatic and cellular assays. These inhibitors
are anti-mitotic, leading to cancer cell death. In vivo, Array's lead KSP
inhibitors caused marked tumor regression in preclinical models of human
cancer at tolerated doses, often leading to durable responses. These highly
soluble inhibitors can be delivered intravenously without requiring enabling
formulations. Based on these preclinical results and the medical community's
growing interest in this target, we are accelerating development of a lead
compound into regulated safety assessment testing.
Additionally, Array will be presenting an update on its ErbB-2 / EGFR
inhibitor, ARRY-334543 at the conference:
Presentation: "ARRY-334543, a potent, reversible, ATP-competitive ErbB
receptor family inhibitor, in clinical development"
Date: March 18, 2006
ErbB-2 / EGFR Inhibitor Program
ARRY-334543 is an oral, selective, reversible, small molecule tyrosine
kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. The compound possesses
improved physiochemical properties relative to compounds directed at these
targets currently in clinical development, providing superior exposure and
equivalent or greater efficacy in preclinical models of human cancer.
ARRY-334543 is currently in a Phase I clinical trial.
Other Array Anti-cancer Programs:
ErbB-2 Selective Inhibitor Program
We have also identified potent, orally active, selective inhibitors of
ErbB-2, that demonstrate efficacy in ErbB-2 driven models of human cancer and
enhanced efficacy in combination with Herceptin(R). We continue to evaluate
additional selective inhibitors of ErbB-2 in advanced preclinical pharmacology
and safety studies.
Array continues to study ARRY-142886 (AZD6244), a potent, selective,
orally active small molecule MEK inhibitor in a Phase Ib clinical trial in
cancer patients. An update of this compound will be given at the 2006 AACR
annual meeting in April.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small molecule drugs
to treat life threatening and debilitating diseases. Our proprietary drug
development pipeline is focused on the treatment of cancer and inflammatory
disease and includes clinical candidates that are designed to regulate
therapeutically important targets. In addition, leading pharmaceutical and
biotechnology companies collaborate with Array to discover and develop drug
candidates across a broad range of therapeutic areas. For more information on
Array, please go to www.arraybiopharma.com .
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
significant risks and uncertainties, including those discussed in our annual
report filed on form 10-K for the year ended June 30, 2005, and in other
reports filed by Array with the Securities and Exchange Commission. Because
these statements reflect our current expectations concerning future events,
our actual results could differ materially from those anticipated in these
forward-looking statements as a result of many factors. These factors
include, but are not limited to, our ability to achieve and maintain
profitability, the extent to which the pharmaceutical and biotechnology
industries are willing to in-license drug candidates for their product
pipelines and to collaborate with and fund third parties for their drug
discovery activities, our ability to out-license our proprietary candidates on
favorable terms, our ability to continue to fund and successfully progress
internal research efforts and to create effective, commercially viable drugs,
risks associated with our dependence on our collaborators for the clinical
development and commercialization of our out-licensed drug candidates, the
ability of our collaborators and of Array to meet drug objectives, including
clinical trials, tied to milestones and royalties, and our ability to attract
and retain experienced scientists and management. We are providing this
information as of March 14, 2006. We undertake no duty to update any
forward-looking statements to reflect the occurrence of events or
circumstances after the date of such statements or of anticipated or
unanticipated events that alter any assumptions underlying such statements.
SOURCE Array BioPharma Inc.
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193,
/Web site: http://www.arraybiopharma.com